Market Update: How Australian Markets Performed on 21st July 2020?

  • Jul 21, 2020 AEST
  • Team Kalkine
Market Update: How Australian Markets Performed on 21st July 2020?

At the close of the trading session on 21st July 2020, Australian equity market ended in green. The benchmark index S&P/ASX200 stood at 6156.3 with a rise of 154.7 points. During the last five days, the index has gained 3.62%. S&P/ASX 200 Consumer Discretionary (Sector) went up by 3.09% to 2,519.9. S&P/ASX 200 Industrials (Sector) ended at 5,733.7, with an increase of 2.53%. At the end of the same session, All Ordinaries closed at 6268.8, reflecting a rise of 156.5 points or 2.56%.

S&P/ASX200 Weekly Performance (Source: ASX)

On ASX, the share price of Immuron Limited (ASX: IMC) witnessed a sharp rise of 248.98% to $0.855 per share. The stock of Mesoblast Limited (ASX: MSB) soared by 10.448% to $3.700 per share.

S&P/NZX50 settled at 11,737 with a rise of 1.59%. The share price of Blackwell Global Holdings Limited (NZX: BGI) inched up by 25.00% to NZ$0.070 per share. The stock of New Zealand Oil & Gas Ltd (NZX: NZO) rose 8.62% and closed the session at $0.630 per share. On the other hand, the stock of Cooks Global Foods Limited (NZX: CGF) tumbled by 8.16% to NZ$0.045 per share.

Recently, we have written an article on Dark Horse Resources (ASX: DHR), and the readers can view the content by clicking here.

Share Increase Witnessed in IMC’s Share Price

Immuron Limited (ASX: IMC) recently announced that IMM-124E used to manufacture Travelan® and Protectyn® demonstrated antiviral activity against COVID-19 virus in the laboratory studies.

The company added that in-vitro assessment of the neutralization of SARS-CoV-2 was performed on four production lots of product used to manufacture Travelan® and Protectyn®. Also, the company’s technology platform offers a potential new oral therapeutic approach to target SARS-CoV-2 in the GI Tract.

Mesoblast Limited Ended in Green on 21st July 2020.

Mesoblast Limited (ASX: MSB) recently notified the market that Oncologic Drugs Advisory Committee (ODAC) of USFDA has scheduled a meeting on 13th August 2020 to review data supporting MSB’s Biologics License Application (BLA) for approval of RYONCIL™ for the treatment of steroid-refractory acute graft versus host disease in children.

Currently, there are no FDA-approved treatments in the US for children under 12 with SR-aGVHD, a potentially life-threatening complication of an allogeneic bone marrow transplant for blood cancer.

For the nine months ended 31st March 2020, the company reported a rise of 113% in revenue to US$31.5 million against US$14.8 million. The company reported a decline of 34% in loss after tax, which was supported by 113% increase in total revenues and a 15% decrease in research and development expenditure.

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. All pictures are copyright to their respective owner(s). Kalkinemedia.com does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.

 

There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK